Immuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour. Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information about immuno-oncology specifically as it applies to renal cell carcinoma. Click here for more information.
Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Clinical Cancer Advances 2017 highlights the most important clinical advances of the past year and previews where cancer science is headed. Advances highlighted
Dr. Laurence Albiges, Oncologist, head of the GU Tumor Board at the Gustave Roussy speaking during ESMO 2016 about how immunotherapy has had an impact on the field of renal cell carcinoma (RCC). Watch the video.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC), according to Dr Basma Greef, of the department of oncology at the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom. She and her co-author, professor Tim Eisen, published an article in the British Journal of Cancer suggesting that researchers are introducing a renaissance of immunotherapy in the treatment of RCC. Read more
Has Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care? A panel led by Dr. Michael Atkins discusses the current state of immuno-oncology for kidney cancer.
IKCC launches an educational website for immuno-oncology for kidney cancer. Powerful Patient interviews Deb Maskens about this effort and its goals.